衡量私募股权在紧急医疗和麻醉学领域的透和整合
Loren Adler1, Conrad Milhaupt1, Samuel Valdez2
1Brookings Institution, 1775 Massachusetts Avenue NW, Washington, DC 20036, United States.
Health affairs scholar
|May 17, 2024
概括
私募股权和上市公司在2009年至2019年期间显著增加了麻醉和急诊医学医生集团的所有权,这有助于市场集中和意外计费的担忧.
科学领域:
- 医疗保健经济学 医疗保健经济学
- 医疗保健服务研究 医疗服务研究
- 医生实践管理 医生实践管理
背景情况:
- 私募股权 (PE) 和上市公司参与医疗保健,特别是麻醉和急诊医学,已与意外医疗收费有关.
- 对于这些公司实体在专业医生集团中推动的历史投资模式和市场整合的理解有限.
研究的目的:
- 调查麻醉和急诊医学医生团体内整合的趋势.
- 从2009年到2019年量化私募股权和上市公司所拥有的集团的市场份额的增长.
主要方法:
- 构建一个新的数据集,以确定麻醉和急诊医学医生团体的所有权结构.
- 在十年内 (2009-2019) 分析市场集中和所有权趋势.
主要成果:
- 在麻醉和紧急医疗方面,当地市场度的大幅增加被观察到.
- 由私人医疗机构或上市公司拥有的医生集团显著扩大了其国内市场份额.
- 这些实体的麻醉市场份额从3.2%增长到18.8%;在2009年至2019年期间,紧急医疗市场份额从8.6%增长到22.0%.
结论:
- 私募股权和上市公司显著增加了他们在麻醉和急诊医学中的存在和整合力量.
- 这些发现突出了这些医学专业的所有权格局的重大转变,这可能会对医疗保健成本和患者计费做法产生潜在影响.
相关概念视频
Drug Concentrations: Measurements
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma —...
Plasma —...
Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


